Financial Highlights Financial Highlights

Performance Highlights

（Millions of Yen）

55th term
2019/9		 56th term
2020/9		 57th term
2021/9		 58th term
2022/9		 59th term
2023/9		 60th term
(Estimated)
2024/9
Net Sales 34,391 32,304 32,645 35,426 40,889 48,926
Operating Income 4,173 3,139 3,349 3,777 3,858 4,907
% of Operating Income 12.1% 9.7% 10.3% 10.7% 9.4% 10.0%
Ordinary Income 4,169 2,983 3,250 3,725 4,519 5,562
% of Ordinary Income 12.1% 9.2% 10.0% 10.5% 11.1% 11.4%
Profit Attributable to Owners of Parent 2,962 2,085 2,432 2,696 3,435 6,185

*From the beginning of the fiscal year ending September 30, 2022, we have changed the accounting policies on which it relies, and accordingly, the above figures are based on the application of those policies.

*60th Net income figures are based on the revised forecast disclosed on November 27, 2023.

  • Net Sales

    Net Sales

  • Operating Income / % of Operating Income

    Operating Income / % of Operating Income

  • Ordinary Income / % of Ordinary Income

    Ordinary Income / % of Ordinary Income

  • Profit Attributable to Owners of Parent

    Profit Attributable to Owners of Parent

Sales by Therapeutic Category

（Millions of Yen）

55th term
2019/9		 56th term
2020/9		 57th term
2021/9		 58th term
2022/9		 59th term
2023/9
Hormone drugs 10,741 10,363 11,758 13,301 16,973
Diagnostic drugs 10,827 8,570 8,310 7,447 7,672
Cellular function affecting drugs 932 966 1,002 948 2,331
Metabolic drugs 3,074 3,216 2,917 2,318 2,136
Vitamin drugs 407 379 401 868 1,232
Nervous system & sensory organs drugs 1,099 1,200 1,170 924 749
Other drugs not mainly for therapeutic purpose - - - 274 666
Antibiotics & Chemotherapeutics 820 689 595 651 630
Others 5,836 5,874 5,702 5,825 5,029
Foreign operation (OLIC) 2,539 2,532 2,131 2,866 3,467
Total 36,279 33,793 33,990 35,426 40,889

*From the beginning of FY9/22, to apply "The Accounting Standards for Recognizing Revenues" (corporate accounting standard No. 29), the abovementioned FY9/22 and FY9/23 by therapeutic category is the figure after the application of new accounting standards.

Sales Breakdown by Therapeutic Category

Key Management Indicators

（Millions of Yen）

55th term
2019/9		 56th term
2020/9		 57th term
2021/9		 58th term
2022/9		 59th term
2023/9
ROE 7.9% 5.3% 6.7% 7.9% 8.9%
ROA 7.3% 4.9% 5.2% 5.3% 5.6%
EPS* 97.04 Yen 66.94 Yen 90.54 Yen 111.01 Yen 141.37 Yen
R & D Expenses 2,052 3,060 2,446 2,485 3,184
% of R & D Expenses
(Net Sales)		 6.0% 9.5% 7.5% 7.0% 7.8%
Capital Expenditures** 1,965 2,965 3,392 7,150 3,652

*From the beginning of the fiscal year ending September 30, 2022, we have changed the accounting policies on which it relies, and accordingly, the above figures are based on the application of those policies.

  • ROE

    ROE

  • ROA

    ROA

  • EPS*

    EPS

  • R & D Expenses / % of R & D Expenses

    R & D Expenses / % of R & D Expenses

  • Capital Expenditures**

    Capital Expenditures
  1. A two-for-one split of common shares took place on July 1, 2018
  2. Capital expenditure includes acquisition cost of property. plant and equipmeent. software acquisition and lease agreement.